论文部分内容阅读
目的:应用酶联免疫分析检测白术对泻剂结肠大鼠血清中SP含量的影响,进而探讨白术对泻剂结肠的作用机制,为白术的临床应用提供进一步的依据。方法:造模成功后,将造模组大鼠随机分为模型组、白术组、莫沙必利组、自然恢复组,模型组予以立即处死取材。白术组、莫沙必利组以及自然恢复组继续予以相应剂量药物灌胃,时间为30d,并检测大鼠粪便干湿重比、结肠传输时间、酶联免疫分析检测SP含量。结果:与模型组比较,白术组、莫沙必利组大鼠粪便干湿重比以及结肠传输时间均变小,有统计学意义(P<0.05),酶联免疫分析检测结果显示:与模型组比较,白术组、莫沙必利组大鼠SP含量有明显升高,均有统计学意义(P<0.05),而白术组与莫沙必利组之间比较无显著性差异。停药一月后白术组与莫沙必利组粪便干湿重比以及结肠传输时间有统计学差异(P<0.05)。结论:单用白术能够提高泻剂结肠大鼠血清中SP的含量,从而达到兴奋肠管,促进肠蠕动,改善症状的作用。并且停药后白术的远期疗效优于莫沙必利,所以有临床应用的价值。
OBJECTIVE: To detect the effect of Atractylodes macrocephalae on the content of SP in the serum of laxative colon rats by enzyme-linked immunosorbent assay (ELISA), and to explore the mechanism of action of Atractylodes on laxative colon, providing further evidence for the clinical application of Atractylodes. Methods: After successful modeling, rats in model group were randomly divided into model group, Atractylodes group, mosapride group and spontaneous recovery group. The model group was sacrificed immediately. Atractylodes group, mosapride group and spontaneous recovery group were given the corresponding dose of drug gavage, the time was 30d, and the dry weight ratio of wet and dry stool, colon transit time, enzyme-linked immunosorbent assay SP content. Results: Compared with the model group, the dry weight ratio and the transit time of the feces in the Atractylodes and Mosapride groups were significantly decreased (P <0.05). The results of enzyme-linked immunosorbent assay showed that compared with the model group, (P <0.05). There was no significant difference between Atractylodes group and Mosapride group (P> 0.05). There was a significant difference in dry-wet weight ratio of feces and transit time of colon between Atractylodes and Mosapride groups after stopping drug administration in January (P <0.05). Conclusion: Atractylodes macrocephala alone can improve the content of SP in the serum of laxative colon rats, so as to achieve excitatory intestine, promote bowel movements and improve symptoms. And the long-term efficacy of Atractylodes after stopping is better than mosapride, so the value of clinical application.